Pharmacokinetics and Safety of Clofazimine in Children With Rifampicin-Resistant Tuberculosis

Abstract Background We described the pharmacokinetics and safety of clofazimine in children treated for multidrug/rifampicin-resistant tuberculosis (MDR/RR-TB). Methods Children aged <18 years were eligible. Clofazimine was administered by weight-based dosing. Sparse and semi-intensive pharmacoki...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	The Journal of infectious diseases Ročník 231; číslo 5; s. e873 - e881
Hlavní autori:	Hughes, Jennifer A, Solans, Belén P, Garcia-Prats, Anthony J, Draper, Heather R, Schaaf, H Simon, Nielsen, James C, Nortier, Elri, Courtney, Ingrid, Palmer, Megan, van der Laan, Louvina, Savic, Radojka M, Hesseling, Anneke C
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	US Oxford University Press 15.05.2025
Predmet:	Adolescent Antitubercular Agents - administration & dosage Antitubercular Agents - adverse effects Antitubercular Agents - pharmacokinetics Antitubercular Agents - therapeutic use Child Child, Preschool Clofazimine - administration & dosage Clofazimine - adverse effects Clofazimine - pharmacokinetics Clofazimine - therapeutic use Female Humans Infant Male Rifampin - pharmacology Rifampin - therapeutic use Tuberculosis, Multidrug-Resistant - drug therapy pharmacokinetics clofazimine children safety tuberculosis
ISSN:	0022-1899, 1537-6613, 1537-6613
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!